Arcus Biosciences presented data for casdatifan plus cabozantinib

Arcus Biosciences (RCUS) presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Arcus is pursuing a broad development program in both the immuno-oncology-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings.
Confident Investing Starts Here:

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

10 hours ago

• Business Insider

GE HealthCare to present portfolio of precision care at SNMMI

At this year's Society of Nuclear Medicine and Molecular Imaging, SNMMI, Annual Meeting, GE HealthCare (GEHC) is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. 'Precision care is the future of oncology-and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry-ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Confident Investing Starts Here:

Buzz Feed

2 days ago

• Buzz Feed

Lizzo Talks About Using Ozempic For Weight Loss

There's no point in stressing out over speculation and rumors regarding Lizzo — she's an open book. On a June 19 episode of the Just Trish podcast, Lizzo admitted that she tried Ozempic and other GLP-1 drugs, which are used to regulate type 2 diabetes and obesity, at one point in her "weight release" journey. Over the years, the "Truth Hurts" singer has been rather forthcoming with her fitness journey, documenting it on social media and sharing her progress with her fanbase. "I tried everything," she told Trisha Paytas. "Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same item." In the podcast, Lizzo shut down critics of Ozempic and GLP-1 drugs, noting that people are not "cheating" by using the products. "It's not easy," Lizzo said. "It's a drug to help somebody with something they're struggling with. I think people... it's their way of being fat phobic when you're telling someone they're cheating." "They tell people they're cheating by getting that weight loss surgery. I heard about that weight loss surgery. That shit sounds very hard actually. A lot people felt like they almost died on the table, and they got so sick after getting the weight loss surgery. That shits not easy." "I feel like people just like to make fun of fat people. Whether you're big or small or got small, they like to make fun of us," she said. Lizzo claimed that she started noticing different results when adding meat back into her diet. "What did it for me is it was not being vegan," she said. "Because when I was vegan, I was consuming a lot of fake meats, I was eating a lot of bread, I was eating a lot of rice and I had to eat a lot of it to stay full." In her opinion, the "fake sugar and weird shit" in processed foods was holding her back, causing her to eat 3,000 to 5,000 calories a day. "When I started actually eating whole foods and eating, like, beef and chicken and fish," she said, "I was actually full and not expanding my stomach by putting a lot of fake things in there that wasn't actually filling me up." "I feel like I worked really, really hard and I was intentional what I did with my body," she added. And that's that! Take that shame somewhere else because Lizzo doesn't play that. Watch the full episode of Lizzo on the Just Trish podcast here.

Yahoo

2 days ago

• Yahoo

Canadian North Resources Announces Results of 2025 Annual and Special Meeting of Shareholders

TORONTO, June 21, 2025 (GLOBE NEWSWIRE) -- Canadian North Resources Inc. ('CNRI' or 'the Company,' TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero) is pleased to announce the voting results of its Annual and Special Meeting of Shareholders held on June 19, 2025, in Mississauga, Ontario. A total of 73,621,572 common shares were voted at the Meeting, representing approximately 64.4% of the Company's issued and outstanding common shares (114,325,317). Election of Directors Shareholders approved the re-election of all five nominees to the Board of Directors. The directors elected to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed are: Nominee % For % Withheld Lee Q. Shim 99.99% 0.00% Kaihui Yang 99.99% 0.00% Aier Wang 99.99% 0.00% Henderson Tse 99.99% 0.00% Michael Weeks 99.99% 0.00% Appointment of Auditors Shareholders approved the reappointment of **MNP LLP**, Chartered Professional Accountants, as the Company's auditor for the ensuing year and authorized the Board to fix the auditor's remuneration. Auditor % For % Withheld MNP LLP 100% 0.00% Stock Option Plan Shareholders also ratified and approved the Company's 10% rolling **Stock Option Plan**, pursuant to which the Board of Directors may allocate options to directors, officers, employees, consultants, and other service providers of the Company. Resolution % For % Withheld Approval of Stock Option Plan 99.99% 0.00% Dr. Kaihui Yang, President and Chief Executive Officer, commented, 'We are pleased with the outcome of this year's meeting and the continued support from our shareholders. With strong participation, we remain focused on executing our strategic objectives and delivering long-term value.' Additional information regarding the matters approved at the meeting is available in the Company's Management Information Circular dated May 23, 2025, filed on SEDAR+ ( NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. About Canadian North Resources North Resources Inc. is an exploration and development company focusing on the critical metals for the clean-energy, electric vehicles, battery and high-tech industries. The company is advancing its 100% owned Ferguson Lake nickel, copper, cobalt, palladium, and platinum project in the Kivalliq Region of Nunavut, Canada. The Ferguson Lake mining property contains a substantial National Instrument 43-101 compliant Mineral Resource Estimate announced on March 19 2024, which include Indicated Mineral Resources of 66.1 million tonnes (Mt) containing 1,093 million pounds (Mlb) copper at 0.75%, 678Mlb nickel at 0.47%, 79.3Mlb cobalt at 0.05%, 2.34 million ounces (Moz) palladium at 1.10gpt and 0.419Moz platinum at 0.19gpt; and Inferred Mineral Resources of 25.9Mt containing 558Mlb copper at 0.98%, 333Mlb nickel at 0.58%, 39.6Mlb cobalt at 0.07%, 1.192Moz palladium at 1.43gpt and 0.205Moz platinum at 0.25gpt. In particular, 80% of the Indicated Mineral Resources is Open Pit with 52.7Mt at 0.65% copper, 0.43% nickel, 0.05% cobalt, 0.97gpt palladium and 0.17gpt platinum, which provides a solid Mineral Resource base for the initial development of a potential large mine. The Mineral Resource model indicates significant potential for resource expansion along strike and at depth over the 15 km long mineralized belt and a number of undefined mineralization zones and prospective areas. (Refer to 'Independent Technical Report on the Mineral Resource Estimate for the Ferguson Lake Project, Nunavut, Canada ('the Technical Report')', prepared by SRK Consulting and Ronacher McKenzie Geoscience Inc., effective March 19, 2024, filed by the Company to SEDAR at on May 3, 2024. The Technical Report has also been posted on the Company's website at Qualified Person:Dr. Trevor Boyd, and Technical Advisor for Canadian North Resources, a qualified person as defined by Canadian National Instrument 43-101 standards has reviewed the technical content of this news release and has approved its dissemination. Further information please visit the website at or contact: Dr. Kaihui Yang, President and CEOPhone: 905-696-8288 (Canada)1-888-688-8809 (Toll-Free)Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data